Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM F SYMMANS and THOMAS A BUCHHOLZ.
Connection Strength
0.722
-
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
Score: 0.146
-
Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012 May 04; 14(3):R72.
Score: 0.105
-
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res. 2003 Jul; 9(7):2406-15.
Score: 0.057
-
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003 Jun 15; 97(12):2960-71.
Score: 0.057
-
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003 Jan-Feb; 9(1):33-41.
Score: 0.055
-
Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002 Nov-Dec; 8(6):461-8.
Score: 0.054
-
Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16.
Score: 0.034
-
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 09; 310(14):1455-61.
Score: 0.029
-
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
Score: 0.024
-
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7909-16.
Score: 0.021
-
Prognostic value of initial clinical disease stage after achieving pathological complete response. Oncologist. 2008 Jan; 13(1):6-15.
Score: 0.019
-
Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007 Oct; 194(4):527-31.
Score: 0.019
-
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007 May; 18(5):874-80.
Score: 0.018
-
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 01; 13(1):228-33.
Score: 0.018
-
Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg. 2006 Jul; 203(1):64-72.
Score: 0.017
-
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
Score: 0.017
-
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005 Jun 07; 102(23):8315-20.
Score: 0.016
-
Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. Cancer Genet Cytogenet. 2003 Mar; 141(2):148-53.
Score: 0.014